French trial opens in diabetes-diet drug scandal

Jacques Servier, center, founder of Servier Laboratories, sits with his lawyers during the opening of the trial at Nanterre's court house, outside Paris, Monday, May 14, 2012. A French court has opened the first of trials over a drug for diabetes commonly used to lose weight and suspected of killing at least 500 people. The pharmaceutical group Servier is suspected of "aggravated deception" for hiding the fact that the drug known as Mediator contained an amphetamine, benfluorex _ removed from the market in 2009 after being found to thicken heart valves. (AP Photo/Michel Euler)

(AP) -- The first French trial has begun over a diabetes drug that was also used to lose weight and is suspected in the deaths of at least 500 people.

The pharmaceutical group Servier is suspected of "aggravated deception" for hiding the fact that the drug known as Mediator contained an amphetamine called - which was taken off the market in 2009 after being found to thicken .

However, another investigation is underway and lawyers for Servier were arguing Monday against holding the current trial claiming that the laboratory could be judged twice on the same grounds.

The nature of benfluorex was allegedly hidden to obtain approval for the drug, first marketed in 1976. So far, charges have been filed against seven people, including drugmaker chief Jacques Servier.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Recommended for you

FDA to start regulating lab-developed tests

Jul 31, 2014

(AP)—The Food and Drug Administration announced Thursday it will begin regulating laboratory-developed tests, a growing class of medical diagnostics that have never before been subject to federal oversight.

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

User comments